Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer

A study that enrolled 30 patients with advanced colorectal cancer, who had not previously received any specific drug treatment, was conducted to develop and study a three-component regimen with oral fluoropyrimidine tegafur (Ftorafur) in outpatient practice. The study evaluated the time to disease progression (TDP), the overall survival (OS) of patients, who received irinotecan + oxaliplatin + Ftorafur in the first-line therapy, as well as the effectiveness and safety of this regimen. 6 patients received a 3-week chemotherapy cycle (Fig. 1), 24 patients – a 2-week chemotherapy cycle (Fig. 2). The preliminary results of the study have been obtained. The median OS was not reached, the median TDP was 8.5 months. In Group I, there was partial regression of metastasis in 3/6 patients, and prolonged disease stabilization (≥ 6 months) in 3 patients. The therapeutic effect (partial remission + long-term stabilization ≥ 6 months) was observed in all patients. The duration of TDP was from 6 to 15 months. In group II, the effect was evaluated in 24 patients, who received at least 2 chemotherapy cycles. 14/24 patients had a partial response (PR), of which 4 (16.6%) patients were radically operated, 6 patients elicited disease stabilization. Thus, control over the disease was achieved in 83.33% of patients in Group II. Oxaliplatin combined with irinotecan and fluorafur was effective, had an acceptable toxicity profile, and therefore, can be used in debilitated patients with disseminated disease.

1. Kaprin AD. Malignant neoplasms in Russia in 2013 (morbidity and mortality). Under the editorship of Kaprin AD, Starinsky VV, Petrova GV, M.: Hertsen Moscow Oncology Research Center - branch of FSBI NMRRC of the Ministry of Health of Russia, 2015. 250 p.

2. Manzyuk LV, Perevodchikova NI, Gorbunova VA, et al. Ftorafur is the first oral fluoropyrimidine in the treatment of metastatic colorectal cancer. Sovremennaya Onkologiya, 2001, 3 (4): 32-34.

3. Semenov NN. Combined treatment for colorectal liver metastases. Russkiy Medicinskiy Zhurnal, 2002, 24: 1109-1111.

4. Tyulyandin SA, Tryakin AA, Fedyanin MYu. Chemotherapy for patients with advanced colon cancer. Sovremennaya Onkologiya, 2010, 2: 18-24.

5. Gorbunova VA, Oryol NF, Besova NS, et al. Advances in clinical chemotherapy for malignant tumors. Rossiyskiy Bioterapevticheskiy Zhurnal, 2003, 2: 15-26

6. Dobrova NV. The combination of tegafur (ftorafura), lecovorin and oxaliplatin (TELVOX) is a new effective regimen of first-line chemotherapy for colorectal cancer metastases. RMJ, 2011, 1: 18-24.

7. Lichinitser MR, Semenov NN. New prospects for using Oxaliplatin (Eloxatin) Pharmateca, 2004, 18: 21-25.

8. Lichinitser MR. Oxaliplatin (Eloxatin): new treatment options for patients with cancer and lymphoma. Mezhdunarodnyy Zhurnal Medicinskoy Praktiki, 2001, 2: 69-72.

9. Lichinitser MR. Oxaliplatin (Eloxatin): new treatment options for patients with cancer and lymphoma Provisor, 2001.19: 39-41

10. Semenov NN. Oxaliplatin (Eloxatin) activity in platinum-sensitive tumors. Pharmateca, 2005, 18: 63-65.

11. Zhukova LG, Lichinser MR, Semenov NN, et al. A study of the efficacy and safety of iritene (irinotecan) + fluorouracil + leucovorin in the first-line chemotherapy for metastatic colorectal cancer. Pharmateca, 2007, 18: 84-86.

12. Gutorov SL. Irinotecan in the treatment of colon cancer. Russkiy Medicinskiy Zhurnal, 2005.13: 884-887.

13. Dobrova NV. The use of Xeloda in the treatment of metastatic colorectal cancer. Pharmateca, 2010, 17: 44-50.

14. Dobrova NV. The use of Xeloda in the treatment of patients with metastatic colorectal cancer. Onkologia, 2011, 1: 41-45.

15. Lichinitser MR, Semenov NN, Paschenko NV. Capecitabine (Xeloda) in the treatment of colorectal cancer and breast cancer: new opportunities. Pharmateca, 2002, 12: 17-20.

16. Fedyanin MYu, Tryakin AA. Capecitabine and fluorouracil in the treatment of colorectal cancer and gastric cancer: an analysis of direct comparative studies Pharmateca, 2011, 17: 20-26.

17. Fedyanin MYu, Tryakin AA. Capecitabine and fluorouracil in the treatment of colorectal and gastric cancer: an analysis of direct comparative studies. Klinicheskaya Onkologiya, 2012, 1: 115-118.

18. Chau I et al. Treatment in advanced colorectal cancer: what when and how? Br. J. Cancer, 2009, 100(11): 1704-1719.

19. Tournigand C et al. FOLFIRI followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J. Clin. Oncol., 2004, 22(2): 229-237.

20. Masi G et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg. 2009, 249: 420-425.

21. Vasile E et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer, 2009, 100(11): 1720-1724.

22. Ychou M et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth. Pharmacol, 2008, 62(2): 195-201.

23. https://www.nccn.org/professionals/physician_ gls/default.aspx.

24. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J ClinOncol, 2004; 22: 1209–14.

25. Falcone A et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol, 2007, 25(13): 1670-1676.

26. Vasile E et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer, 2009, 100(11): 1720-1724.

27. Van Cutsem E et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. J. Clin. Oncol, 2010, 281 (abstr.): 4000.

28. Bokemeyer C et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 2009, 27(5): 663-671.

29. Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner KS, Wolf M, and Gansert J. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. Journal of Clinical Oncology, 2010, 28(31): 4697-4705. doi: 10.1200/JCO.2009.27.4860.